Neuroscience

ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping SolutionViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution

ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling…

11 months ago
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

11 months ago
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsOvid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm…

11 months ago
Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

MORRISTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries…

11 months ago
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug ResistanceMIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug Resistance

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug Resistance

New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL /…

11 months ago
Aetna Policy Update Expands TMS Availability for Adolescents With DepressionAetna Policy Update Expands TMS Availability for Adolescents With Depression

Aetna Policy Update Expands TMS Availability for Adolescents With Depression

Coverage criteria consistent with recent FDA clearance for NeuroStar TMSMALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:…

11 months ago
GlassView Taps Amazon Ads’ Stellantis US Agency & Enterprise Lead as VP, Client PartnershipsGlassView Taps Amazon Ads’ Stellantis US Agency & Enterprise Lead as VP, Client Partnerships

GlassView Taps Amazon Ads’ Stellantis US Agency & Enterprise Lead as VP, Client Partnerships

NEW YORK, July 19, 2024 /PRNewswire/ -- With a 20 year career in producing data-driven solutions for clients at Amazon…

11 months ago
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditionsNew data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic…

11 months ago
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidanceNovartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance

Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance

Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up…

11 months ago
Venture-Backed The Way Launches First-of-Its-Kind Meditation Training AppVenture-Backed The Way Launches First-of-Its-Kind Meditation Training App

Venture-Backed The Way Launches First-of-Its-Kind Meditation Training App

Taught by renowned Zen Master and author Henry Shukman, new app offers program of long-term meditation training that guides users…

11 months ago